alendronate / Generic mfg. - LARVOL DELTA

Impacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis. (PubMed, Clin Interv Aging) - "Participants were stratified into five groups based on prior anti-osteoporosis treatments: no treatment (NT), alendronate (ALN), zoledronic acid (ZOL), teriparatide (TPT), and raloxifene (RAL). These findings indicated that prior anti-osteoporosis treatments differentially influenced BMD responses to 1-year Dmab therapy. While patients who had previously been treated with ZOL had limited subsequent BMD improvement, patients who had previously used TPT and had lower baseline BMD benefited more."

Journal • Real-world evidence • Osteoporosis • Rheumatology

Cost-effectiveness of opportunistic osteoporosis screening using chest radiographs with deep learning in Germany. (PubMed, Aging Clin Exp Res) - "AI-driven chest radiographs for opportunistic osteoporosis screening is a cost-effective strategy for German women aged 50+, with the potential to significantly improve public health outcomes, reduce fracture burdens and address healthcare disparities. Policymakers and clinicians should consider implementing this scalable and cost-effective screening strategy."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Yak milk improves retinoic acid-induced osteoporosis by promoting intestinal calcium absorption. (PubMed, J Dairy Sci) - "However, no improvement was observed in the alendronate sodium (ALN) group...These data suggest that yak milk promotes calcium absorption by upregulating the expression of the TRPV6 calcium channel, thereby improving OP. This study highlights the importance of yak milk as a dietary factor for bone health."

Journal • Osteoporosis • Rheumatology • TRPV6

Amino-bisphosphonates enhance CD8+ T cell responses to vaccine antigens by an ATRAID dependent mechanism (IMMUNOLOGY 2025) - "Here, we have examined the effect of alendronate (ALD), a nitrogen containing BP, on the response of CD8+ T cells to immunization with a model vaccine consisting of chicken ovalbumin (OVA) and CpG as an adjuvant...Moreover, ALD combination with OVA + CpG enhanced the response of adoptively transferred ATRAID sufficient OVA-specific OT-I CD8 T cells in WT recipients, but failed to do so in ATRAID-/- recipients. These data indicate that ALD is capable of enhancing the CD8+ T cell response to exogenous antigens by a mechanism that is critically dependent on the presence of ATRAID in one or more cell types other than CD8 T cells.Keywords: Cells T Cells; Processes Cytotoxicity"

Infectious Disease • Osteoporosis • CD8 • GZMB • IFNG

Improving the effector function of Vd2+ ?d T cells through modulating platelet activity. (IMMUNOLOGY 2025) - "Human Vδ2+ T cells were expanded for 18 days with alendronate and subsequently cocultured with platelets at 1:20 and 1:50 ratios for 18 hours...Flow cytometric analysis revealed that the cytotoxic capacity of Vδ2+ T cells increased by over 20% in target cell killing in a manner that can be reversed by treating the cultures with platelet inhibitors. These findings suggest that platelets may enhance the cytotoxic potential of Vδ2+ T cells, underscoring a promising avenue for developing platelet-mediated immunotherapies.Keywords: Cells T Cells; Molecules Cytokine Receptors Cytokines T Cell Receptors; Processes Cytotoxicity"

IO biomarker

Multiscale characterization of jawbone treated with osteoporosis therapeutic agents. (PubMed, J Mech Behav Biomed Mater) - "The objective of the current study was to determine whether treatments of bisphosphonate (alendronate (ALN)), parathyroid hormone (PTH), and their combination have an effect on the jawbone in estrogen deficient rats...These findings are different from those of lumbar vertebrae in the same rats that showed a significant bone alteration by OVX and treatments. Thus, the current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw."

Journal • Osteoporosis • Rheumatology

Challenges in Endocrine Function Testing During Clinical Cancer Drug Trials: False Positives Due to Heterophilic Antibodies (ENDO 2025) - "She was referred to the Endocrinology Department for osteoporosis management, and after evaluation, she was treated with Denosumab and cholecalciferol...Two months after switching to alendronate, PTH was measured at 1171 pg/mL...Following the initiation of osteoporosis treatment, the patient participated in a clinical trial to assess the safety and efficacy of Oregovomab in combination with Paclitaxel, Carboplatin, and Bevacizumab... Heterophilic antibodies have been recognized for a long time, but caution is needed as mouse-derived antibodies are still used in early-stage research. These antibodies can cross-react with non-homologous antigens, interfere with immunoassays, and lead to inaccurate test results.*. .*"

Clinical • Endocrine Disorders • Oncology • Osteoporosis • Ovarian Cancer • Pituitary Gland Carcinoma • Rheumatology • Solid Tumor

Buffered soluble alendronate treatment preventing rebound following denosumab discontinuation in erosive hand OA: a randomized trial (EULAR 2025) - No abstract available

Clinical

A rare parathyroid lipoadenoma in a patient with sporadic multiglandular primary hyperparathyroidism – pitfalls in preoperative localization and pathological diagnosis (ESPE-ESE 2025) - "She had been treated with alendronate for osteoporosis of the distal third of the radius, fulfilling an indication for parathyroidectomy in asymptomatic PHPT...Both methods correctly localized only one of two pathological parathyroid glands in the present case, highlighting the fact that multiglandular PHPT is often associated with equivocal parathyroid imaging and a high rate of surgical failure. Supported by MH CZ - DRO (Institute of Endocrinology - EÚ, 00023761)"

Clinical • Endocrine Disorders • Metabolic Disorders • Osteoporosis • Rheumatology

Case Report and Follow-up of Juvenile Paget's Disease Caused by TNFRSF11B Mutations in Sibling Pair (ESPE-ESE 2025) - "After alendronate sodium was administered, the symptoms of the siblings were alleviated, they could stand and walk without any help, and the serum total alkaline phosphatase (ALP) level was significantly decreased... After bisphosphonate treatment, ALP levels decreased significantly and skeletal symptoms improved in both cases. Conclusion Early identification and treatment of JPD caused by TNFRSF11B gene mutation can significantly improve the quality of life of patients. Bisphosphonates are effective therapeutic agents, and early intervention can prevent severe bone deformities and functional impairment."

Case report • Clinical • Musculoskeletal Diseases • Orthopedics • Rare Diseases • TNFRSF11B

The role of Bisphosphonates in the prevention and treatment of Heterotopic Ossification following Spinal Cord Injury: A systematic review. (PubMed, Injury) - "A total of 11 studies were included: nine investigating etidronate, one on alendronate, and one on pamidronate. However, the available evidence remains insufficient to draw definitive conclusions about the optimal use of bisphosphonates in this population. Further well-designed clinical trials are required to elucidate their preventive and therapeutic efficacy in managing HO after SCI."

Journal • Review • CNS Disorders • Orthopedics

Alendronate repositioning as potential anti-parasitic agent targeting Trichinella spiralis inorganic pyrophosphatase, in vitro supported molecular docking and molecular dynamics simulation study. (PubMed, BMC Chem) - "Moreover, molecular dynamics simulation, through the analysis of RMSD, RMSF, RG, SASA and cluster analysis, proved the prolonged effective inhibition of ALN on T. spiralis inorganic pyrophosphatase, as an essential surface protein required for molting and developmental process of intestinal larval stages. Thus, ALN might be a valuable drug candidate for the treatment of trichinellosis and warrant further investigation in animal models of disease."

Journal • Preclinical • Hepatology • Infectious Disease • Osteoporosis • Rheumatology

Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis: An Updated Systematic Review and Meta-analysis. (PubMed, J Clin Rheumatol) - "This comprehensive meta-analysis provides robust evidence that romosozumab is an effective and safe treatment option for postmenopausal osteoporosis, with superior effects on BMD and bone formation biomarkers compared with other interventions. These findings support the use of romosozumab to improve clinical outcomes in this patient population."

Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures (ENDO 2025) - "Title: The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures Introduction: Atypical femur fractures (AFFs) are a rare but serious complication linked to prolonged use of bisphosphonates and denosumab...After seven years on alendronate, she sustained a complete right AFF requiring intramedullary nailing...This case emphasizes the need for clear guidelines on screening for AFFs and the potential role of FFI in personalized imaging protocols to enhance patient care.*. .*"

Diabetes • Dyslipidemia • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus

Iodine-Induced Thyrotoxicosis Leading to Severe Osteoporosis: A Case Report (ENDO 2025) - "Common sources include iodized salt, amiodarone, and seaweed-based supplements such as kelp. We report a case of iodine-induced thyrotoxicosis secondary to kelp consumption, resulting in severe osteoporosis, emphasizing the importance of dietary awareness in thyroid management.CaseA 58-year-old woman with osteoporosis, low BMI, and premature ovarian insufficiency (POI) was evaluated for worsening bone density despite prior treatment with alendronate...She was advised to avoid excessive iodine and was treated with prednisone. She also started denosumab but was lost to follow-up...Comprehensive care should include dietary counseling and, when needed, psychiatric evaluation to address behavioral patterns contributing to excessive supplement use and related health risks.*. .*"

Case report • Clinical • Cardiovascular • Endocrine Disorders • Movement Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psychiatry • Rheumatology • Women's Health

Comparative Effects of Denosumab and Alendronate on Incidence of Type 2 Diabetes Mellitus in Patients with Osteoporosis: A Nationwide Study (ENDO 2025) - "Given the observational nature of the study and potential residual confounding factors, further prospective research with longer follow-up and detailed clinical data is warranted to clarify the long-term metabolic effects of antiosteoporotic agents.*. .*"

Clinical • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

From Bone Density to Bone Death: Osteonecrosis of the Jaw in a Patient with Minimal Risk Factors (ENDO 2025) - "BRONJ occurs in 0.01%-0.06% of OP patients and up to 8% of cancer patients receiving higher and more frequent doses of antiresorptive medications or jaw radiation.Here we present a case of a 70-year-old female with a history of OP, who developed osteonecrosis of the jaw after 5 years of alendronate use with limited risk factors. Non-BP therapies, such as denosumab or teriparatide, could be considered to prevent further bone loss and fractures, but also carries the risk of ONJ, although data is limited.*. .*"

Clinical • Endocrine Disorders • Musculoskeletal Diseases • Oncology • Osteoporosis • Pain • Rheumatology

Effects of bisphosphonates & denosumab on bone mineral density in patients with osteoporosis - A study from central India. (ENDO 2025) - "Three groups of treatment alendronate- N=13, Zoledronic acid- N=39 & denosumab- N=11 allocated. Treating such patients had resulted rewarding results.*. .*"

Clinical • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Optimal Timing of Denosumab with Parathyroidectomy in the Setting of Primary Hyperparathyroidism​ (ENDO 2025) - "She started alendronate, calcium citrate, and high dose ergocalciferol prior to presenting to endocrinology...She remained on prednisone for 3 additional years while on denosumab... Parathyroidectomy was scheduled in proximity to the next denosumab dose since timing is important due to rebound resorption phenomenon and increased risk of vertebral fractures after delayed or missed denosumab doses. However, peri-procedural hypoparathyroidism and severe hypocalcemia can result if potent anti-resorptive therapy prevents liberation of calcium from bone. Considering this, denosumab was given 8 weeks after parathyroidectomy."

Cardiovascular • Dermatology • Endocrine Disorders • Grave’s Disease • Hypoparathyroidism • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psoriasis • Rheumatology • Secondary Hyperparathyroidism

EURODEC: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) (clinicaltrials.gov) - P=N/A | N=125 | Recruiting | Sponsor: 424 General Military Hospital | Trial completion date: Nov 2026 ➔ Nov 2027 | Trial primary completion date: Nov 2026 ➔ Nov 2027

Trial completion date • Trial primary completion date • Osteoporosis • Rheumatology

Focusing on spinal stenosis: emerging discoveries concerning Alendronate-induced risks and genetic drug targets. (PubMed, J Orthop Surg Res) - "This study reveals an alendronate-spinal stenosis association, offering insights for clinical prevention. It also identifies new genetic drug targets, opening new treatment pathways for spinal stenosis."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Safety profile and risk factors associated with incadronate disodium treatment in breast cancer patients with bone metastases: A retrospective analysis. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Retrospective data • Breast Cancer • Oncology • Solid Tumor

Percutaneous Kyphoplasty combined with different anti-osteoporosis drugs for the treatment of osteoporotic vertebral compression fractures. (PubMed, Pak J Med Sci) - "The extent of vertebral loss in Group-C was significantly lower than Groups A and B (P<0.05). In the treatment of osteoporotic vertebral compression fractures after percutaneous kyphoplasty, a combination of calcium therapy with calcitonin and alendronate sodium had a positive effect, which may effectively improve bone density, pain, and functional status, and reduce the incidence of vertebral body fractures."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology

Retraction notice to "Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes" [Diabetes Res. Clin. Pr. 93 (2011) 166-173]. (PubMed, Diabetes Res Clin Pract) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Rare Case of Nail Patella Syndrome and Osteoporosis (ENDO 2025) - "Alendronate was prescribed from 2005 to 2012...Due to her low C-telopeptide and improvement in her DXA a bisphosphonate holiday was reinitiated in 2024.Clinical lessons: Patients with nail patella syndrome have a higher risk of early osteoporosis and should be monitored closely to evaluate for early intervention.*. .*"

Clinical • Allergic Rhinitis • Dermatology • Endocrine Disorders • Gastroesophageal Reflux Disease • Immunology • Inflammation • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Osteoporosis • Pulmonary Disease • Renal Disease • Rheumatology • Urology